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Background. Safe opioid prescribing and effective pain care are particularly important issues in the United States,
where decades of widespread opioid prescribing have contributed to high rates of opioid use disorder. Because of the
importance of clinician-patient communication in effective pain care and recent initiatives to curb rising opioid over-
dose deaths, this study sought to understand how clinicians and patients communicate about the risks, benefits, and
goals of opioid therapy during primary care visits. Methods. We recruited clinicians and patients from six primary
care clinics across three health systems in the Midwest United States. We audio-recorded 30 unique patients currently
receiving opioids for chronic noncancer pain from 12 clinicians. We systematically analyzed transcribed, clinic visits
to identify emergent themes. Results. Twenty of the 30 patient participants were females. Several patients had multi-
ple pain diagnoses, with the most common diagnoses being osteoarthritis (n = 10), spondylosis (n = 6), and low
back pain (n = 5). We identified five themes: 1) communication about individual-level and population-level risks, 2)
communication about policies or clinical guidelines related to opioids, 3) communication about the limited effective-
ness of opioids for chronic pain conditions, 4) communication about nonopioid therapies for chronic pain, and 5)
communication about the goal of the opioid tapering. Conclusions. Clinicians discuss opioid-related risks in varying
ways during patient visits, which may differentially affect patient experiences. Our findings may inform the develop-
ment and use of more standardized approaches to discussing opioids during primary care visits.
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Chronic pain and opioid use disorder present enormous
public health challenges to the US health care system.
Estimates of chronic pain prevalence range from 25 to
100 million US adults.1,2 Pain contributes an estimated
$600 billion in health care costs and lost worker produc-
tivity annually.2 Between 1999 and 2015, health care pro-
viders quadrupled their prescribing of opioid pain
relievers, while overdose deaths increased dramatically.3
In 2017, over 47,000 people died in the United States
from opioid overdoses.4 Importantly, primary care clini-
cians prescribe nearly half of all dispensed opioid
prescriptions.5 To help combat opioid-related risks, the
Centers for Disease Control and Prevention (CDC) pub-
lished the 2016 Guideline for Prescribing Opioids for
Chronic Pain that targets primary care treatment of
chronic noncancer pain.6
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Reflected in the CDC Guideline and other opioid pre-
scribing best practices is the need for clinicians to regu-
larly assess, and talk with their patients about, opioid-
related risks, benefits, and treatment goals when consid-
ering or managing chronic opioid therapy. However,
because primary care clinicians are often caring for multi-
ple patient conditions during short clinic visits,7–9 it is
unclear how accurately or comprehensively clinicians dis-
cuss opioid-related risks, benefits, and goals with their
patients. At the same time, accurate and comprehensive
communication is important to ensure that patients
understand opioid-related health risks and benefits, and
that clinicians and patients have a common understand-
ing of appropriate treatment goals. Indeed, prior research
has found that patients may have inaccurate perceptions
of opioid-related risks and benefits,8,10 and patients and
clinicians may not share the same outcome goals.11
Given the importance of effective primary care com-
munication to achieve safe and guideline-concordant
opioid prescribing, the purpose of this study was to
describe how clinicians communicate about risks, bene-
fits, and goals of opioid therapy during primary care vis-
its. This knowledge may help identify communication
deficits in patient-clinician interactions about opioid-
related risks, benefits, and goals of opioid therapy. This
knowledge may also aid in developing policy, education,
and other interventions that increase safe and patient-
centered pain care.
Methods
We conducted an observational study that analyzed audio
recordings of clinic visits between primary care clinicians
and patients with chronic noncancer musculoskeletal pain
who were receiving opioids. This study, which focuses on
patients receiving opioids, is part of a larger study to
understand clinical decision making for chronic pain care,
including care that does not involve opioids. We analyzed
clinic visits occurring between May 2016 and May 2017.
The Indiana University Institutional Review Board
approved this study. A complete Consolidated Criteria
for Reporting Qualitative Research checklist (COREQ)
for our study can be found in Appendix 1.
Population and Sample
We recruited primary care clinicians from three health
care systems in Indiana and Illinois. Eligible clinicians
included physicians, physician assistants, and nurse practi-
tioners who prescribe opioids. We purposefully recruited
participants to obtain a sample that was diverse in practice
type and location, clinician age, race/ethnicity, and sex.
We also sought to have a diverse representation among
the patients, including variations in age, race/ethnicity,
sex, and complexity of pain condition. We recruited clini-
cians using e-mail invitations, in-person presentations at
clinic staff meetings, and word-of-mouth. Next, we identi-
fied patient participants based on medical record review
and recommendations from recruited clinicians. We delib-
erately sought patient diversity by recruiting from health
clinics that serve diverse patient populations. Eligible
patients were required to speak English, have a current
chronic musculoskeletal pain condition, have no history
of cancer in the 3 years before their visit, and currently
receiving opioids. Because our larger study also recruited
patients not currently receiving opioids, we identified
patients with current opioid prescriptions by reviewing
transcripts of their clinic visits.
Before we approached the patients, their primary care
clinician confirmed their eligibility as a patient with chronic
noncancer musculoskeletal pain. Both clinician and patient
participants provided written informed consent to partici-
pate in the study. Patient participants were compensated
with a $25 gift card for their time in the study.
Procedure
After notifying their primary care providers, a member
of our research team approached eligible patients in
clinic waiting areas or the exam room before scheduled
visits. Patients were given sufficient time to read the con-
sent form and ask any clarifying questions of the recrui-
ter. After obtaining informed consent, the researcher
placed an audio recorder in the exam room to capture all
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auditory interactions between the patient and primary
care clinician. After the visit, the audio recorder was
removed, and the audio file was transferred to a secure
computer server. Next, a professional transcriptionist
transcribed the audio recordings. Research team mem-
bers de-identified each of the transcripts before analysis.
Analysis
We used a combination of deductive and inductive analyti-
cal approaches to explore patterns and themes related to
clinicians’ descriptions of risks, benefits, and goals of opioid
therapy during visits with patients.12,13 First, to ground our
analysis in established clinical practice recommendations,
we used a deductive or ‘‘top-down’’ approach to develop a
codebook based on a subset of CDC Guideline recommen-
dations that focus on communication about opioid-related
risks, benefits, and goals of opioid therapy.6 Specifically,
the Guideline recommends ‘‘. . . clinicians should establish
treatment goals with all patients, including realistic goals
for pain and function . . .’’ (Recommendation 1) and ‘‘. . .
clinicians should discuss with patients known risks and rea-
listic benefits of opioid therapy . . .’’ (Recommendation 2).
The codebook included the following codes: 1 risks—
utterances about current or potential for negative health
effects of opioids; 2) benefits—utterances about current or
potential positive health effects of opioids; and 3) goals—
utterances about desired changes to pain therapy being uti-
lized and/or utterances about the intended health effects of
using opioids.
Second, two experienced and trained coders (ECD
and OM) individually applied our initial codes to each
clinic visit transcript in Dedoose qualitative analysis soft-
ware Version 7.7.6.14 The coders then met to discuss the
fit of the codebook and adjusted codes as needed, result-
ing in a revised coding template. During this process, we
also used an inductive or ‘‘bottom-up’’ approach to
describe new categories of meaningful data and make
modifications to the codebook.12 For example, during
this process, we divided the benefits code into two parts.
The first code captured utterances about the positive
health effects of opioids. The second code captured utter-
ances about the lack of positive health effects of opioids.
Next, the two coders independently applied the codes
from the modified codebook. The codes were applied at
the utterance level, and codes were not mutually exclu-
sive.15 The coders met after the first transcript and peri-
odically thereafter to discuss coding differences and
reach consensus. After coding all transcripts, each coder
individually analyzed the coded text for patterns and
themes, using the overarching research questions as a
guide.16 During analysis, the coders met periodically to
review emerging themes and reconcile any disagreements.
We finished collecting and analyzing additional tran-
scripts after two rounds of coding. Initially, we included
and coded 24 transcripts. Next, we included six additional
transcripts to determine whether any new themes emerged
and if our emerging themes were consistent in the new
transcripts. When no new themes emerged in the second
round of coding, we concluded our data collection.
Finally, to ensure our analysis captured patients’
responses and interactions with their clinicians, we fur-
ther examined the transcript excerpts within each theme.
This process generated additional codes focused on
patients’ responses. Two coders individually identified
patient response–related codes, met to compare codes
and reach consensus, and then applied these codes to all
transcripts. The coders met and reviewed each excerpt
until they reached consensus.
Throughout our data analysis we used several estab-
lished qualitative methodology procedures to ensure
rigor and validity of our findings. Specifically, we prac-
ticed reflexivity by continually questioning interpreta-
tions of data and becoming aware of one’s own
preconceptions and biases. We also actively sought out
the depth of description (seeking out rich, particular
details of participants’ words) and searched for alterna-
tive explanations of the data.17–19
Results
Overview of Patients, Clinicians, and Visits
We analyzed 30 clinic visits across 3 health systems, 2 not-
for-profit and 1 academic. The clinic visits took place
across 6 clinics, with 21 visits at urban clinics and 9 at
rural clinics. The clinic visits involved 11 physicians and 1
family nurse practitioner. Clinicians’ specialty included
family medicine (n = 8), internal medicine (n = 3), and
general medicine (n = 1). Clinicians’ experience ranged
from 2 to 30 years of practice. Half of the clinicians were
female; 9 identified as white, 2 identified as African
American, and 1 identified as Asian.
Twenty of the 30 patient participants identified as
female. Several patients had multiple pain diagnoses (as
reported by their clinician following the visit), with the
most common diagnoses being osteoarthritis (n = 10),
spondylosis (n = 6), low back pain (n = 5), radiculopa-
thy (n= 5), and spinal stenosis (n= 4). Additional infor-
mation about study participants is located in Table 1.
Nearly all clinicians had discussions related to risk,
benefits, or goals of opioid therapy. Discussions included
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five themes in clinician communication about risks, bene-
fits, and goals of chronic opioid therapy. Patient responses
to clinician utterances generally fell into three main
categories: listening, agreeing, and providing or asking for
more information about a topic.
Communication About Individual-Level and
Population-Level Risks
Clinicians varied in their opioid-related risk utterances,
sometimes describing individual (i.e., patient-specific) risk
factors and/or sometimes describing population-level
risk statistics. A few clinicians described individual-level risk
factors and negative outcomes associated with opioid use
(e.g., comorbid disease or fall risk) specific to the patient.
In some instances, clinicians described individual-level risk
factors as rationale for recommending reduction or discon-
tinuation of opioids. In this example, a clinician described
how a patient’s comorbid condition, chronic obstructive
pulmonary disease (COPD), when combined with opioids,
may increase the severity of respiratory suppression:
Clinician 3: . . . we do not want you on the narcotics a long
time. The thing that you are getting is one of the side effects
is that it can suppress breathing. So you already have COPD
you have enough trouble breathing just with your COPD.
Patient 5: I breathe a lot better now that I quit smoking
though.
Some clinicians also described opioid-related risks at the
population level. For example, clinicians referenced current
rates of opioid addiction or overdose. These risks referred
to someone other than the patient. For example, this clini-
cian communicated opioid-related mortality statistics:
Clinician 6: . . . when people are on long-term pain medicine,
and things are getting tighter and tighter as you know, it is
hard because people are dying. We have almost 100 people a
day dying of narcotic overdose every day. It is actually, I
have not been able to talk to _____ at the school today . . .
for years and years, the number one cause of death in teen-
agers has always been car crashes. In the last 6 years, opioid
overdose. So teenagers in America today are more likely to
die of an opioid overdose than a car crash.
Patient 18: I do understand that.
In response to individual and population-level risk com-
ments, some patients listened to the information pro-
vided through short responses to the clinician, similar to
the quote above. We also saw some patients agreeing
and/or requesting additional information about the risks
as well as providing some of their own information to
the risk discussion like Patient 5 who has COPD. Patient
5 provides more information about how her recent life-
style change has made it easier for her to breathe.
Table 1 Description of Clinician (n= 12) and Patient
(n= 30) Samples
Urban Clinics Rural Clinics
Clinicians, n (n = 12)
Sex
Female 5 1
Male 4 2
Race
White 6 3
African American 2 0
Asian 1 0
Specialty
Family medicine 5 3
Internal medicine 3 0
General Medicine 1 0
Years of practice
\10 2 2
10–20 6 0
.20 1 1
System type
Not-for-profit 8 3
Academic 1 0
Patients, n (n = 30)
Sex
Female 17 3
Male 4 6
Race
White 13 9
African American 8 0
Age, years
18–30 0 1
31–40 4 1
41–50 3 0
51–60 6 4
61–70 6 2
71+ 2 1
Paina
Diagnoses
Osteoarthritis 7 3
Spondylosis 6 0
Low back pain 2 3
Radiculopathy 2 3
Spinal Stenosis 4 0
Fibromyalgia 2 1
Rheumatoid arthritis 2 0
Location(s)
Spine 16 2
Knee 6 1
Shoulder 2 2
Hip 2 1
aSome patients had multiple pain diagnoses and pain locations. As a
result, totals shown are more than the number of patients.
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Communication About Policies or New Practices
Related to Opioids
Some clinicians also described current opioid policies or
changes to prescribing to their patients. Most of these clin-
icians worked in the same health care system. In nearly all
cases, this discussion occurred in the context of opioid
dose reduction or discontinuation. For example, this clini-
cian described the CDC Guideline for Prescribing Opioids
for Chronic Pain and suggested that the patient’s current
dose was too high6:
Clinician 6: . . . Cause we’re kind of . . . I think I showed you
before, the CDC came out with some guidelines and we’re
kind of exceeding those. We’ve got dose . . . of course you’re
a big guy and everything like that.
Another clinician described her health system’s policy
that recommends limiting opioid prescriptions:
Clinician 3: Now at HEALTH SYSTEM really doesn’t want
us writing more than 2 pain pills a day. If we said we were
going to reduce these from 4 to 3, do you think you would
still manage or how would that be for you?
Patient 5: No that wouldn’t work. That just wouldn’t work.
I know we talked about that last time.
In most circumstances, clinicians referenced policies or
changes in common practice to introduce the topic of
tapering or as support for the decision to taper. Many
patients listened to clinicians’ explanations about opioid
policies and practices and were occasionally not given a
chance to respond or confirmed with short responses,
such as ‘‘I’m listening’’ and ‘‘I understand.’’
Communication About the Limited Effectiveness
of Opioids for Chronic Pain Conditions
Some clinicians described opioids as medications that
can reduce pain in the short-term but not provide long-
term benefit for patients’ underlying pain conditions.
These utterances often occurred in the context of discus-
sion about nonopioid treatment options and/or about
identifying the underlying cause of the patients’ pain.
For example,
Clinician 5: The challenge here is making sure we are treat-
ing your pain with the right medication. Yea the Norco
(hydrocodone and paracetamol) will make the pain go away,
but it will not necessarily treat the cause of the pain, and if
we treat the cause of the pain then maybe long term you will
not have to take [opioids] . . .
Patient 17: Well I’m thinking I might have hurt it lifting
her. I still do a lot of lifting and she’s [granddaughter] gotten
heavier . . .
Similarly, another clinician focused on the importance of
understanding the underlying cause of pain rather than
relying on opioids:
Clinician 7: You know as far as the pain medication. We
need to figure out what’s going on. That way we can kind of
get at the root cause and you know just throwing pills at
you is not a good, long-term plan here . . .
Most patients listened or agreed with clinicians’ discus-
sions of limited benefits from opioids and in a couple
instances mentioned their acceptance that their pain may
always linger.
Clinician 8: There’s certain things I’m just not going to be
able to fix for you and I’m glad that you have that, you
know, mind set about it, it certainly makes our job a lot
easier.
Patient 20: Especially I have a lot of arthritis all over my
body and that’s the same thing with the fibromyalgia, you
just have a lot of pain. I’ve had it for 17 years. I guess I just
learned to deal with it and pray that I can at least stay on
the tramadol to help my legs.
Communication About Nonopioid Treatment
Options for Chronic Pain
Many clinicians discussed using nonopioid therapies (e.g.,
nonsteroidal anti-inflammatory drugs, topical lidocaine,
or physical therapy) as potentially better approaches to
treating patients’ pain. In the example below, one clini-
cian suggested several non-opioid treatment options in
addition to not increasing the opioid dose:
Clinician 7: Instead of just upping what we are already doing
actually keeping the Norco (hydrocodone and paracetamol)
where we are but help attack the pain in another way. . . .
Lyrica (pregabalin) and gabapentin. Physical therapy would
be great . . .
Some clinicians also suggested additional assessments and
consultations to identify the root cause of the patients’ pain
condition (e.g., imaging or referral to surgery).
The majority of the patients agreed with or discussed
additional information during nonopioid treatment discus-
sions. Patients were often onboard with trying new medica-
tions to treat the pain and sometimes wanted clarification
of medication administration, logistic information about
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tapering/receiving these new treatments such as transporta-
tion, or to share other relevant information. For example,
Patient 26 agrees with the new treatment plan with the
expectation that it will better control her pain.
Clinician 10: I would be interested to see how a combination
of the Cymbalta and low dose Lyrica help with things and if
that allows us to continue our efforts and kind of wean
down that Oxycodone.
Patient 26: Yeah, if I can have an alternative that worked
better, hey I’m in.
In the context of a couple physical therapy discussions,
clinicians emphasized the importance of pursuing physical
therapy to avoid falls and improve physical function.
Beyond these, functional discussions varied from a short
statement at the beginning or end of a visit to patients set-
ting goals such as playing with grandkids or going upstairs.
Communication About the Goal of the Opioid
Tapering
Some of the clinicians had discussions about tapering the
opioid medications that patients were currently taking.
Tapering-related utterances ranged from clinicians
expressing discomfort with a current opioid dose to clini-
cians directly recommending dose reduction. Some of
these communications were suggestive of ongoing discus-
sions about opioid tapering across several visits. For
example, one clinician responded to a patient’s request
for an increase in an opioid dose by suggesting opioid
tapering and her discomfort with the current dose:
Patient 1: Really I need something better for pain. I really
do. If you could up my milligram.
Clinician 1: I won’t be able to do that, actually we’re work-
ing on decreasing it, because you’re on more than I’m really
comfortable prescribing.
In this example, the clinician recommended nono-
pioids for pain in support of the tapering process:
Patient 26, Clinician 10: I would be interested to see how a
combination of the Cymbalta (duloxetine) and low dose
Lyrica (pregabalin) help with things and if that allows us to
continue our efforts and kind of wean down that oxycodone.
Most patients agreed with tapering discussions while a
couple requested more information about the tapering
process such as how much they would be going down.
Clinician 5: So instead of like taking away the 7s and going
straight to the 5s you take them away incrementally.
Patient 11: What are you thinking of this?
Clinician 5: It is a little bit slower, but I think you will feel
less of a change.
Additional illustrative quotes related to each of the
five themes can be found in Figure 1.
Discussion
Currently, the United States is facing a public health crisis
related to opioid use disorder and overdose deaths.20,21 A
significant driver of this crisis has been widespread opioid
prescribing for pain, a prevalent symptom that affects
millions of Americans. Primary care clinicians prescribe
more opioids than any other provider type.5 Yet primary
care clinicians are time constrained during visits7,9 and
report limited pain management knowledge.22 Therefore,
this study aimed to describe how primary care clinicians
communicate with patients about opioid-related risks,
benefits, and goals. This is an important step in ensuring
clinician communication is consistent with current clinical
guidelines, and in supporting safe prescribing and effec-
tive clinician-patient relationships.
The primary finding of this study is that clinicians
actively communicated about opioid-related risks in mul-
tiple ways. We observed clinicians explaining to patients
that increased opioid doses could cause sedation and
other adverse effects.23,24 In some cases, clinicians articu-
lated these risks in terms of individual risk factors, such
as increased risk of respiratory problems in a patient with
COPD.25 More often, clinicians described population-
level risk information, such as opioid-related mortality
statistics. Clinicians also referenced policies or current
practices that recommended caution in opioid dosing,
which could be interpreted as indirect discussions about
risks. Similar to prior research, we found that clinicians
referenced policies as a facilitator in tapering discussions
to avoid blame and discomfort when communicating
with the patient.26 Given that clinical guidelines recom-
mend clinicians actively assess and discuss risks, this
finding is generally encouraging; however, with recent
attention to guideline misapplication, this discussion type
may be a concern for patients whose risks do not out-
weigh the benefits.27,28 At the same time, it is unclear if
and how different approaches to communicating opioid-
related risks differentially affect patients. The use of
different risk communication approaches may have
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Theme Illustrative Quotations
Communication 
about
individual-level 
risksa
Clinician: The problem is how do we get your pain better without putting you on medicines that are 
going to make you feel more groggy and also that won't have other long-term side effects and make you 
more likely to fall (Patient 15, Clinician 7) 
Now on this pain medicine, like I said, I'm going to give you #20 just in case you take them and they 
loop you out, I don't want to give you a ton. So you're probably going to want to call me the end of this 
week, to let me know whether it is working or not (Patient 23, Clinician 9) 
Communication 
about
population-
level risksb?
Clinician: So it can cause lots of side effects, and I can give you a whole handout about this, there's the 
constipation, possible to get addictive, confusion, causes people to fall, it can change how your body 
feels pain so actually you have more pain as time goes on... so all that stuff. (Patient 15, Clinician 7) 
Patient: That's fine, but here's the way I understand opiates for people who take them recreationally, 
they work as a. 
Clinician: A stimulant. 
Patient: A stimulant, yeah. So it works like cocaine or methamphetamine or something like that. 
Clinician: ___ actually a lot of people just want to be numb. They want to not feel anything. They want 
to be sedated. That is why trazodone, sertraline and Zoloft (Sertraline), seroquel, all of these ___ can be 
abused. Some people just want to be knocked out, you know? I'm not saying that is what you want, you 
know, but that's what we have to be careful of. (Patient 3, Clinician 1) 
Communication 
about policies 
and practice 
Clinician: The ___ policy wants us to cut down on your Norco (hydrocodone and paracetamol) to 2 a 
day but I’m just gonna say you know what, you need your 4 a day.” (Patient 6, Clinician 3) 
Clinician: I think the tough thing about chronic pain is that it’s very easy to slip out of control, so I'm 
not someone to write large quantities for long periods of time because, you know, if you get a big 
bottle, it’s very easy to just take a lot of them initially and then _____ problems, so that's kind of what 
we're doing. (Patient 3, Clinician 1) 
Communication 
about the 
limited 
effectiveness of 
opioids
Clinician: So it's important to me that you try again to see if it will help your back, because that's really 
the underlying thing that will help your back. The pain medicine isn't going to help, it's just going to 
make the pain go away, but it will always be there, unless we do something to help. (Patient 1, 
Clinician 1) 
Clinician: “The reason why I'm pushing the ibuprofen is because you have some inflammation, you saw it 
on your MRI right? And this is a medicine that is actually going to help decrease the inflammation. I think 
that's more helpful, to me, than the Percocet (Oxycodone-Acetaminophen).” (Patient 3, Clinician 1) 
Communication 
about non-
opioid therapies 
Clinician: for your back pain, although you had that for a year, we're going to put you right back on 
your gabapentin which you're out of, back on your Flexeril (cyclobenzaprine), ___ pain. We will keep 
your pain pills where they are right now.” (Patient 8, Clinician 3) 
Clinician: Okay. So let's tell you what ___, so a couple of things, one for your back pain, although you 
had that for a year, we're going to put you right back on your gabapentin which you're out of, back on 
your Flexeril (cyclobenzaprine), ___ pain. We will keep your pain pills where they are right now. I 
(Patient 8, Clinician 3) 
Communication 
about opioid 
tapering goals 
Clinician: Later on in the month, if things are going well with adding the Mobic (meloxicam) and your 
exercises, maybe you could try a half of one [MS Contin] (morphine). Break it in half and see what 
happens. Because our goal eventually is to try to get you off completely. (Patient 12, Clinician 6) 
So one of the things I wanted to talk to you because in the meantime we talked about this the last time. I 
would like to talk about, even though we are talking about this new identified pain, cutting back on our 
pain medications. (Patient 11, Clinician 5) 
Figure 1 Emergent themes with illustrative quotes.
aIndividualized risk discussions occur when a clinician addresses risks specific to that patient.
bPopulation risk discussions occur when a clinician addresses risks about the general population rather than the patient.
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implications for clinician satisfaction as well as patient
satisfaction, treatment adherence, and health behavior.29,30
Evidence shows that clinicians who tailor their risk com-
munication to a specific patient’s case might better inform
patients.29–32 For example, a recent study revealed that
patients preferred to know how opioids may affect their
health based on their unique medical history, as opposed
to population-level concerns.29 Furthermore, more accu-
rate patient risk perceptions may aid conversations about
therapy changes, such as opioid tapering.29 At the same
time, when discussing concerns about risks and aiming to
reduce opioids, a conversation that can be fraught,30,33–36
clinicians may feel more comfortable deferring to a third-
party policy or rule, which cannot be directly negotiated.
When examining utterances about opioid-related risks
from the patient perspective, we observed that most of
the patients listened to clinicians discussing risks without
commenting. Some of the patients wanted to have clari-
fying discussions about risks of opioids. Thus, similar to
prior research our findings suggest that patients may not
fully understand or agree that opioid-related risks apply
to them.29 Additional research is needed to identify bar-
riers that preclude patients from being more actively
engaged in communication about opioid-related risks
with their primary care provider.
We also found that clinicians communicated about
the limited effectiveness of opioids in treating chronic
noncancer pain, especially for improving general out-
comes like physical function.23,37 Such discussions are
encouraging given the limited evidence for the benefit of
long-term opioids in treating chronic noncancer pain.38
We also found that many clinicians discussed the use
of nonopioid therapies for patients’ pain. In some cases,
using nonopioid therapies was described in the context of
clinicians’ goals to maintain or decrease patients’ opioid
doses. While we saw patients often agree or listen to the
proposed changes to their treatment plan, previous litera-
ture suggests patients are not confident about managing
pain without opioid medication.8 This incongruence
between patient preferences and utterances during clinic
visits has the potential to harm patient-clinician relation-
ship and should be explored further.
Our study has a number of strengths. By collecting
direct observations of clinical visits, we obtained a rich
understanding of how chronic pain care is delivered in an
era of increased concern about the risks and potential
benefits of opioid prescribing. Moreover, we observed a
diverse group of clinicians and patients that spanned
rural and urban areas and multiple health systems. Also,
by using a mixed inductive and deductive thematic analy-
sis approach, we were able to gain a more thorough
understanding of how opioids are discussed during
healthcare encounters. Still, our study is not without lim-
itations. Although we reached thematic saturation in our
analysis, having a larger and/or more diverse sample of
clinicians might have elicited a wider range of communi-
cation themes. It is also plausible that patients or clini-
cians who declined to participate may engage in different
discussions about opioids than those who volunteered to
be observed; consequently, we may have missed some
aspects of clinical communication and perspectives
related to risks, benefits, and goals of opioid therapy.
Additionally, we did not assess the dose, type, duration
of opioid therapy, or history of substance use disorder,
all of which might influence communication about opioid
therapy. Also, our study occurred in the Midwestern
United States, and results may not be transferable to
other settings. With that said, this region of the country
has been particularly affected by opioid use disorder,
making it an important area to study. We also recognized
that clinician discussions could have been affected by
being audio recorded. However, we believe that by using
a discreetly placed audio-only recorder, such effects were
minimal. Finally, because we captured a single visit in an
ongoing patient-clinician relationship, we may have
missed other relevant communication about risks, bene-
fits, and goals of opioid therapy. With that said, given
the risks and regulations currently surrounding chronic
opioid therapy, we believe it is reasonable to expect that
some meaningful opioid-related communication occurs
at all primary care visits.
In conclusion, this study provides timely understand-
ing of how clinicians communicate with patients about
common chronic pain conditions and the medications
often used in their treatment. Our findings add to recent
literature that aims to conceptually describe factors
affecting patient-clinician interactions39 and clinical deci-
sion making for chronic pain care.40 Building on our
work, future studies might examine larger samples of
patients and clinicians to estimate the prevalence of the
types of communication we observed as well as the rela-
tive effectiveness of different communication strategies.
Finally, educational efforts and decision support tools
could be designed to help clinicians communicate with
patients in ways that support safe and guideline-
concordant opioid prescribing while minimizing poor
patient experiences.
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